Clinical and Prognostic Features of Rectal Neuroendocrine Tumors Abstract #433

Introduction: Rectal neuroendocrine tumors (NETs) are among the most common NETs.
Aim(s): The primary aim was to identify predictors of survival. The secondary aim was to identify characteristics associated with the presence of metastatic disease.
Materials and methods: From records of the Mount Sinai Division of Gastrointestinal Pathology and the Carcinoid Cancer Foundation, a database of 141 patients was constructed. Statistical analysis was performed and Kaplan Meier curves were created.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Brett M Weinstock
Keywords: net

To read results and conclusion, please login ...

Further abstracts you may be interested in

#28 Prognostic Clinicopathologic Factors in Longitudinally Followed Patients with Metastatic Small Bowel Carcinoid
Introduction: Neuroendocrine tumors demonstrate heterogeneous behavior based upon site of origin and specific histology. Even after controlling for anatomic location, disease stage and histologic grade, registry studies show persistent diversity of outcome in patients with midgut carcinoid.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Mr. Thomas Curran
#307 Prognostic Features in Patients with Metastatic Neuroendocrine Tumor Undergoing Y-90 Embolization
Introduction: Neuroendocrine tumors (NETs) are rare neoplasms originating from enterochromaffin cells. NET patients with liver metastases frequently undergo Yttrium-90 (Y90) embolization.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Michelle Kim
#1666 Prognosis and Incidence in Pancreatic and Gastrointestinal Neuroendocrine Neoplasms with Emphasis on “NET G3”: An Analysis of 198 Cases from Japan
Introduction: Prognostic impact of well differentiated pancreatic neuroendocrine neoplasms (PanNENs) with a Ki67 >20%, provisionally called NET G3, needs to be validated and compared to poorly differentiated neuroendocrine carcinomas (NECs). Moreover, the frequency of NET G3 among gastrointestinal NENs (GI-NENs) has so far not been studied.
Conference: 14th Annual ENETS conference (2017)
Category: Pathology, grading, staging
Presenting Author: Atsuko Kasajima
Keywords: NET G3, GEP-NEN, GI-NET
#1485 Validation of a Blood Neuroendocrine Tumor Gene Signature, the NETest, in a Netherlands NET Cohort
Introduction: The CgA has limitations as a monoanalyte biomarker. The introduction of a PCR-based multi-analyte analysis of 51 genes (NETest) has been proposed as more accurate.
Conference: 13th Annual ENETS conference (2016)
Category: Biomarkers
Presenting Author: Dr Margot Tesselaar
Authors: Tesselaar M, Korse T, Kidd M, Verbeek W, ...
#1883 Utility of a Circulating NET mRNA Gene Signature for Defining Bronchopulmonary Neuroendocrine Neoplasia and Evaluating Disease Progression
Introduction: Bronchopulmonary NETs (BPNETs) exhibit indolent to aggressive behavior. Imaging, histology and biochemistry are limited in accurately defining malignancy or progression. A blood based NET multigene test is effective in diagnosing GEP-NET progression and therapy response.
Conference: 14th Annual ENETS conference (2017)
Category: Non digestive NETs (bronchial, MTC pheochromocytoma) Pathology, grading, staging
Presenting Author: Professor Mark Kidd
Keywords: NET
Close
Notice
Important Notice:

In preparation of the upcoming ENETS Barcelona 2018 Annual Conference, we have discovered in the world wide web at least one professional entity suggestive of possessing an ENETS mandate for conference registrations. Therefore, we must inform you that 100% of all conference participants are registered through ENETS official website www.enets.org and http://enetsconference.org/. There are no further options to validly register for Barcelona 2018 (or for any other ENETS event).

Please stay away from fraudulent scams abusing the ENETS acronym to register – and charge you above official ENETS conference fees! Such entities, against whom ENETS presses criminal charges, are neither authorized, nor commissioned nor instructed by ENETS to make such representations.